Compass Planning Associates Inc Purchases 5,623 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Compass Planning Associates Inc raised its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 91.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,776 shares of the medical instruments supplier’s stock after purchasing an additional 5,623 shares during the period. LeMaitre Vascular accounts for approximately 1.0% of Compass Planning Associates Inc’s holdings, making the stock its 11th biggest holding. Compass Planning Associates Inc’s holdings in LeMaitre Vascular were worth $988,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of LMAT. Smartleaf Asset Management LLC lifted its holdings in LeMaitre Vascular by 234.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 293 shares during the period. CBIZ Investment Advisory Services LLC raised its position in shares of LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 117 shares during the last quarter. NBC Securities Inc. bought a new stake in shares of LeMaitre Vascular during the 1st quarter valued at $36,000. KBC Group NV lifted its stake in shares of LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after purchasing an additional 410 shares during the period. Finally, Huntington National Bank boosted its position in shares of LeMaitre Vascular by 64.9% in the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock worth $107,000 after purchasing an additional 455 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on LMAT shares. Wells Fargo & Company began coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective for the company. Oppenheimer lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Lake Street Capital upped their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Finally, Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $97.83.

LeMaitre Vascular Trading Up 0.9%

LMAT stock opened at $84.13 on Friday. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The firm has a market cap of $1.90 billion, a PE ratio of 45.97, a P/E/G ratio of 2.22 and a beta of 0.83. The business’s 50-day moving average price is $83.71 and its two-hundred day moving average price is $91.10.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. During the same period in the prior year, the business earned $0.44 EPS. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. On average, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.95%. The ex-dividend date was Thursday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 40.40%.

Insider Activity

In related news, insider Trent G. Kamke sold 2,009 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. This represents a 26.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 4,399 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total value of $374,354.90. Following the transaction, the chief executive officer now directly owns 1,827,003 shares of the company’s stock, valued at $155,477,955.30. This trade represents a 0.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 102,009 shares of company stock worth $8,721,836 over the last quarter. 9.50% of the stock is currently owned by company insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.